Homepage > Company > Media > Pharma News > 2022 > FDA Grants Immune-Onc’s IO-202 Fast-Track Status for Treating AML

FDA Grants Immune-Onc’s IO-202 Fast-Track Status for Treating AML

The FDA has granted Fast-Track designation to Immune-Onc Therapeutics’ IO-202, an experimental myeloid checkpoint inhibitor developed for treating patients with relapsed or refractory acute myeloid leukemia (AML).

Immune-Onc is currently assessing IO-202 alone and in combination with other therapies in a phase 1 trial in patients with AML and chronic myelomonocytic leukemia.

IO-202 works by targeting the leukocyte immunoglobulin-like receptor B4 involved in immune suppression and tumor infiltration. The therapy previously won FDA’s Orphan Drug designation for treating AML in 2020.

February 22, 2022

https://www.fdanews.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)